MD Anderson and Xilis Announce Strategic Collaboration to Advance Novel Technology and Accelerate Therapeutic Development

The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere™ technology in support of preclinical research to accelerate the development of novel cancer therapies.